Positive Transcription Elongation Factor b Phosphorylates hSPT5 and RNA Polymerase II Carboxyl-terminal Domain Independently of Cyclin-dependent Kinase-activating Kinase*

Jae B. KimDagger § and Phillip A. Sharp||

From the  Center for Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 and the Dagger  School of Biological Sciences, Seoul National University, Seoul, Korea 151-742

Received for publication, December 4, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The CDK9-cyclin T kinase complex, positive transcription elongation factor b (P-TEFb), stimulates the process of elongation of RNA polymerase (Pol) II during transcription of human immunodeficiency virus. P-TEFb associates with the human immunodeficiency virus Tat protein and with the transactivation response element to form a specific complex, thereby mediating efficient elongation. Here, we show that P-TEFb preferentially phosphorylates hSPT5 as compared with the carboxyl-terminal domain of RNA Pol II in vitro. Phosphorylation of hSPT5 by P-TEFb occurred on threonine and serine residues in its carboxyl-terminal repeat domains. In addition, we provide several lines of evidence that P-TEFb is a CDK-activating kinase (CAK)-independent kinase. For example, CDK9 was not phosphorylated by CAK, whereas CDK2-cyclin A kinase activity was dramatically enhanced by CAK. Therefore, it is likely that P-TEFb participates in regulation of elongation by RNA Pol II by phosphorylation of its substrates, hSPT5 and the CTD of RNA Pol II, in a CAK-independent manner.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Efficient transcription of full-length proviral DNA of human immunodeficiency virus (HIV)1 is controlled by the viral protein Tat. Tat is expressed early in the viral life cycle and is essential for viral replication and gene expression (1-3). Tat recognizes the bulge region of TAR (transactivation response element), an RNA stem-loop structure located at the 5' end of HIV transcripts (4, 5). Although the precise molecular mechanism by which Tat exerts its transcriptional activation is not completely understood, it has been suggested that Tat stimulates transcription by RNA polymerase (Pol) II predominately at the level of elongation rather than initiation (6, 7).

Recent studies indicate that P-TEFb (positive transcription elongation factor b) is a key cellular factor supporting Tat-dependent elongation (8-12). P-TEFb, originally identified from Drosophila melanogaster, was purified as a suppressor of an inhibitor of elongation by RNA Pol II (8, 9) and is composed of kinase subunit CDK9 and its cyclin partner cyclin T (11-15). P-TEFb efficiently phosphorylates the CTD of RNA Pol II and in fact is associated with elongating RNA Pol II in vitro (16-18). The kinase activity of P-TEFb is sensitive to DRB, an inhibitor of elongation by RNA Pol II. Furthermore, Tat binds specifically to human P-TEFb via a cyclin T subunit (13, 14, 19). A specific cysteine residue, 261 of human cyclin T, is critical for the interaction of Tat with P-TEFb, and rodent cells that encode a cyclin T lacking this cysteine residue are defective for Tat activation (13, 14, 19-23). Finally, depletion of P-TEF from HeLa nuclear extract decreased not only basal transcription but also Tat-dependent transcription elongation (11, 24).

In addition to P-TEFb, Tat-dependent activation of transcription is also regulated by other cellular factors including TAT-SF1 and DSIF (hSPT4 and 5). TAT-SF1 was identified using a partially purified reconstituted reaction that supports Tat-dependent TAR-specific stimulation of elongation (25, 26). TAT-SF1, a phosphoprotein, contains two RNA recognition motifs and a highly acidic domain at its carboxyl terminus (26). TAT-SF1 binds to Tat, and its overexpression can stimulate Tat-dependent activation in vivo (26, 27). In addition, TAT-SF1 forms a protein complex including TFIIF (RAP30), P-TEFb, hSPT5, and RNA Pol II that is thought to mediate Tat-dependent activation in vitro (27-30).

DSIF (hSPT4 and 5) was originally isolated as a factor that renders transcription in vitro inhibitable by DRB (35). DSIF forms a protein complex with the negative elongation factor to inhibit promoter proximal elongation by RNA Pol II (31-34). Release from this inhibition is mediated by P-TEFb, specifically through phosphorylation by its DRB-sensitive kinase CDK9 (32, 34). DSIF is also important for Tat activation, because nuclear extracts depleted of hSPT5 do not support Tat-dependent elongation in vitro (27, 29, 30). Additionally, overexpression of hSPT5 stimulates Tat-specific activation in vivo (27). In yeast, SPT5 increases the efficiency of elongation of RNA Pol II complexes (35).

Several studies have also implicated TFIIH in Tat activation (36-39). TFIIH is a general transcription factor that forms a preinitiation complex with RNA Pol II (40-43). TFIIH is composed of nine polypeptides (p34, p44, p54, p62, CDK7, cyclin H, MAT1, ERCC2, and ERCC3). TFIIH is not only essential for RNA Pol II-dependent transcription but is also important for DNA repair and cell cycle regulation (41, 42). An important component of TFIIH is the CDK7 subunit, which interacts with cyclin H and MAT1 to form CAK (CDK-activating kinase) and phosphorylates the CTD of RNA Pol II (41-44). Recent genetic and biochemical evidence strongly suggests that this phosphorylation of the CTD is important for interaction of the CTD with capping enzymes that modify the nascent transcript (45-47). Surprisingly, these results also showed that the phosphorylation state of the CTD is significantly altered as the polymerase continues to elongate. The CAK, CDK7-cyclin H, is also known to specifically phosphorylate a threonine residue in the T-loop of other CDKs (48, 49). This phosphorylation stimulates the activity of these CDK kinases.

In this study, we have shown that P-TEFb prefers hSPT5 as a substrate as compared with the CTD of RNA Pol II. Unlike other CDKs, CDK9 is not phosphorylated by CAK but undergoes autophosphorylation. These results suggest that P-TEFb mediates RNA Pol II CTD phosphorylation independent of CAK activity during stimulation of elongation.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In Vitro Kinase Assay-- Kinase assays were performed as described previously (9, 11). Briefly, 20 µl of kinase reaction contained 20 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mg/ml bovine serum albumin, 10 µM ATP, 5 µCi of [gamma -32P]ATP, 50-100 ng of substrates, and 10 ng of purified kinases. The reactions were incubated at 30 °C for 5 min. Protein complexes were resolved by SDS-polyacrylamide gel electrophoresis. The gels were dried and exposed to x-ray film. Reaction products were quantified by using a PhosphorImager and the ImageQuant program (Molecular Dynamics).

Preparation of Recombinant Proteins-- Plasmid pBAK-HuCDK9-T1 was kindly provided by D. Price. Recombinant CDK9-cyclin T protein complex was expressed in Hi5 cells by use of baculovirus and was prepared as described previously (11, 14). The full length of CDK9WT (wild type) cDNA was amplified by polymerase chain reaction. CDK9TA and CDK9DN mutant cDNAs were produced by polymerase chain reaction with the following oligonucleotides (only the sense strand): 5'GTCCTGAAGCTGGCAAACTTTGGGCTGGCCCGG3' for CDK9D167N and 5'CAGCCCAACCGCTACGCCAACCGTGTGGTGACA3' for CDKT186A (mutation sites are indicated with underlines). These CDK9 cDNAs were again polymerase chain reaction-cloned to fuse in frame into the pFAST-BacHTa vector (Life Technologies, Inc.). Hi5 cells were infected with baculovirus containing these CDK9 cDNAs with histidine tags at the amino terminus. Recombinant CDK9 proteins were purified as recommended by the manufacturer (Life Technologies, Inc.). For expression of various recombinant hSPT5 proteins, the following plasmids were polymerase chain reaction-cloned from wild type hSPT5 cDNA and fused in frame into the EcoRI and SalI sites of pET28+a (Novagen): FL (full-length), which contains amino acids (aa) 1-1087 of hSPT5; the amino-terminal domain, which contains aa 1-271 of hSPT5; the middle domain, which contains aa 272-756 of hSPT5; the carboxyl-terminal domain, which contains aa 757-1087 of hSPT5; CTR (C-terminal repeat), which contains aa 757-920 of hSPT5. To prepare histidine-tagged hSPT5 proteins, these DNA constructs were transformed into Escherichia coli BL21(DE3), and proteins were induced and purified by affinity chromatography with a nickel-conjugated agarose column as recommended by the manufacturer (Novagen). Recombinant TAT-SF1 protein was prepared as described previously (27). Purified CAK (CDK7-cylin H) and CDK2-cyclin A proteins were kindly provided by N. P. Pavletich.

Western Blots-- Western blots were performed as described previously (27). Briefly, recombinant proteins were resolved by SDS-polyacrylamide gel electrophoresis and then transferred to a polyvinylidene difluoride membrane. The blots were incubated with each antibody and visualized using an ECL kit (Amersham Pharmacia Biotech). Antibodies against CDK9 and the histidine tag were purchased from Santa Cruz Biotechnology and used at a dilution of 1:1000.

Phosphoamino Acid Analysis and Phosphopeptide Mapping-- Phosphorylated hSPT5 proteins were prepared by incubation in a P-TEFb kinase assay as described above. Phosphorylated peptides were resolved in a 4-20% SDS-polyacrylamide gel electrophoresis and then transferred to polyvinylidene difluoride membrane. With phosphopeptides eluted from the membrane, phosphoamino acid analysis and phosphopeptide mapping were performed as described (50, 51), except that plastic cellulose TLC plates (EM Science) and a Multiphor II electrophoretic system were used (Amersham Pharmacia Biotech).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

P-TEFb Phosphorylates hSPT5 and the CTD of RNA Pol II-- DRB inhibits transcription at the stage of elongation in vivo (52, 53). During transcription in vitro, DRB also selectively inhibits elongation as compared with initiation, probably by suppressing kinase activities such as those responsible for CTD hyperphosphorylation (54, 55). Among many CTD kinases, CAK and P-TEFb have relatively well characterized functions in RNA Pol II transcription in vitro. Both kinases are DRB-sensitive (10, 11, 38, 39). As part of the characterization of P-TEFb, the DRB sensitivity of both kinases was examined using baculovirus-expressed P-TEFb (CDK9-cyclin T) and CAK (CDK7-cyclin H). When GST·CTD was used as substrate, the IC50 of DRB was estimated as 2.5 and 20 µM for P-TEFb and CAK, respectively (Fig. 1A). This result suggests that P-TEFb is significantly more sensitive to inhibition by DRB than CAK, which is consistent with previous results (9-11). This observation is also consistent with the inhibition of P-TEFb controlling the DRB-sensitive elongation process both in vivo and in vitro. Approximately 2-5 µM DRB yields a 50% decrease in transcription activity (10, 11).



View larger version (38K):
[in this window]
[in a new window]
 
Fig. 1.   DRB sensitivity of P-TEFb kinase and identification of P-TEFb substrates. A, DRB sensitivities of P-TEFb (CDK9-cyclin T) and CDK7-cyclin H kinase complexes were examined with GST·CTD as substrate. 10 ng of P-TEFb or CDK7-cyclin H complex were used to phosphorylate GST·CTD (100 ng) with indicated amounts of DRB. B, in vitro P-TEFb kinase assay with various substrates. Recombinant P-TEFb (CDK9-cyclin T) complex was mixed with indicated proteins (50 ng) during the in vitro kinase assay. Positions of heavily phosphorylated GST·CTD and SPT5 are marked with arrowheads. Positions of TAT-SF1, cyclin T, CDK9, and histone H1 are marked with arrows on the right. C, titration of recombinant hSPT5 and GST·CTD proteins during the in vitro P-TEFb kinase assay. Indicated amounts of substrates of either hSPT5 or GST·CTD were used with 20 ng of P-TEFb. To get a similar intensity, the film of phosphorylated GST·CTD was exposed two times longer than that of phosphorylated SPT5.

To date, the CTD of RNA Pol II is the best known substrate of P-TEFb. To test whether P-TEFb can phosphorylate other molecules involved in Pol II-dependent transcription, P-TEFb kinase assays were performed with several other substrates: hSPT5, CAK, CDK2-cyclin A, TAT-SF1, and histone H1. GST·CTD was included as a positive control. As shown in Fig. 1B, P-TEFb phosphorylated both GST·CTD and hSPT5 more efficiently than the other proteins tested. In fact, P-TEFb phosphorylated hSPT5 more effectively than GST·CTD at the same substrate concentration (Fig. 1B). We therefore further investigated the enzyme-substrate specificity of P-TEFb. Both hSPT5 and GST·CTD proteins were serially diluted to measure the Km value for P-TEFb (Fig. 1C). The calculated values for hSPT5 and GST·CTD were 18 and 55 nM, respectively. Moreover, because the GST·CTD contains 52 YSPTPSP repeats, each of which is a potential site of phosphorylation, whereas hSPT5 probably contains fewer potential sites, these Km values probably underestimate the preference of hSPT5 as a substrate.

P-TEFb Phosphorylates the Carboxyl Terminus of hSPT5-- To determine the preferential phosphorylation domains of hSPT5 by P-TEFb, hSPT5 was divided into the following three domains: the amino-terminal domain, which is rich in acidic amino acid; the middle domain, which contains KOW motifs similar to those of E. coli NusG proteins; and the carboxyl-terminal domain, which contains CTR heptapeptide repeats (Fig. 2A) (33). Each of the recombinant hSPT5 proteins was histidine-tagged and expressed in E. coli (Fig. 2B). As shown in Fig. 2C, P-TEFb efficiently phosphorylated the carboxyl-terminal domain of hSPT5 rather than the amino-terminal or middle domains, although a low level of phosphorylation of the middle domain was detected. The CTR domain contains multiple serine and threonine residues that could be potential phosphorylation sites by the serine/threonine kinase P-TEFb. To test which amino acids of hSPT5 are phosphorylated by P-TEFb, phosphoamino acid analysis was performed. As shown in Fig. 2D, 75 and 25% of hSPT5 phosphorylations occurred at the threonine and serine residues, respectively, whereas tyrosine phosphorylation was not observed. To confirm that the CTR is the major phosphorylation domain of hSPT5 by P-TEFb, two-dimensional phosphopeptide mapping was performed with recombinant FL and CTR proteins. FL and CTR phosphopeptides produced by digestion with trypsin were resolved on TLC plates. Most of the separated phosphopeptides of the CTR proteins comigrated with those of the FL protein, suggesting that the high affinity phosphorylation sites of hSPT5 are in the CTR domain.



View larger version (58K):
[in this window]
[in a new window]
 
Fig. 2.   Analysis of hSPT5 phosphorylation by P-TEFb kinase. A, schematic of recombinant hSPT5 proteins. The amino-terminal domain contains aa 1-271 of the hSPT5 protein; the middle domain contains aa 272-756 of the hSPT5 protein; the carboxyl-terminal domain contains aa 757-1087 of the hSPT5 protein; and CTR contains aa 757-920 of the hSPT5 protein. NT, amino-terminal domain; MD, middle domain; CT, carboxyl-terminal domain. B, immunoblotting (IB) of recombinant hSPT5 proteins with anti-His antibody. 30-50 ng of histidine-tagged recombinant hSPT5 proteins were resolved via a 4-20% SDS-polyacrylamide gel electrophoresis and immunoblotted with anti-His antibody. C, in vitro P-TEFb (CDK9-cyclin T) assay with various hSPT5 recombinant proteins. 10 ng of P-TEFb kinase were mixed with indicated hSPT5 proteins during the in vitro kinase assay. Positions of phosphorylated CDK9 and cyclin T are marked with arrowheads. D, phosphoamino acid analysis of wild type hSPT5. Phosphorylated full-length hSPT5 proteins were obtained by an in vitro kinase assay with P-TEFb and then analyzed by phosphoamino acid analysis. Positions of phosphoserine (P-S), phosphothreonine (P-T), and free phosphate (Pi) are marked. E, two-dimensional phosphopeptide mapping. Recombinant FL and CTR of hSPT5 proteins were phosphorylated by P-TEFb as in C. Phosphorylated proteins were digested with trypsin (20 units), eluted, and then loaded for TLC.

Phosphorylation of Threonine 186 of CDK9 and Kinase Activity-- The kinase activities of CDKs can be regulated by several mechanisms. The binding of a cyclin partner is one of the activation processes. Some CDKs are activated by phosphorylation of a specific threonine residue in their T-loop. CAK (CDK7-cyclin H) is responsible for phosphorylation in the T-loop of several CDKs including CDK2, 4, and 6 (48, 49). CDK9 shows 39% identity with CDK2, the best characterized kinase whose activity is controlled by CAK. More importantly, CDK9 has a threonine residue at position 186 in the T-loop region that is conserved in the corresponding region of CDK2. Two different point mutants of CDK9 were made to study the functional role of phosphorylation of this site (Fig. 3A). First, threonine 186 of CDK9 was mutated to alanine (CDK9TA), which does not undergo phosphorylation. Second, aspartic acid 167 of CDK9 was mutated to asparagine (CDK9DN), which abrogates its kinase activity. Although catalytically inactive, the latter mutant protein probably folds into a native conformation because it functions as a dominant negative in vivo (10). These CDK9 mutants were expressed in insect cells by use of the baculovirus system and purified. The kinase activity of CDK9 was enhanced 4-5-fold when bound by cyclin T (Fig. 3B, lanes 1, 2, 5, and 6). As expected, CDK9DN had no kinase activity, whereas CDK9TA had approximately the same activity as CDK9WT. (Note that in Fig. 3C a lower amount of CDK9TA than CDK9WT was used in the reactions shown in lanes 3 and 7.) In addition, phosphorylation of CDK9 was detected in CDK9WT and CDK9-cyclin T assays (Fig. 3C, lanes 1, 2, 5, and 6), but it was not detected when CDK9TA was tested. This shows that 1) the CDK9 kinase can undergo autophosphorylation and 2) the primary site of autophosphorylation of CDK9 under these conditions is at Thr-186. In addition, these data indicate that the kinase activity of CDK9 is not strongly dependent upon phosphorylation of the threonine residue in its T-loop.



View larger version (35K):
[in this window]
[in a new window]
 
Fig. 3.   Kinase activity assay with CDK9 wild type and mutant proteins. A, mutation position of CDK9 Dright-arrowN and CDK9 Tright-arrowA (see details under "Experimental Procedures"). B, in vitro kinase assay with CDK9-cyclin T, CDK9WT, CDK9DN, and CDK9TA proteins. 100 ng of GST·CTD (lanes 1-4) and 25 ng of recombinant hSTP5 (lanes 5-8) proteins were used as substrates. C, immunoblotting (IB) of recombinant CDK9 proteins with anti-CDK9 antibody. The same amounts of CDK9 proteins (10 ng) were used for both the in vitro kinase assay (B) and immunoblotting (C).

CDK9 Kinase Activity and Phosphorylation-- Although threonine 186 of CDK9 is dispensable for its kinase activity, it is important to determine whether this conserved threonine of CDK9 could be a substrate for phosphorylation by CAK, which could modulate its kinase activity. Two different approaches were used to test the possibility that CAK could phosphorylate and thus activate CDK9-cyclin T. First, CDK9WT and mutants including CDK9TA and CDK9DN were tested as substrates for CAK. As shown in Fig. 4A, phosphorylation of CDK9WT but not CDK9TA or CDK9DN was observed in the presence of CAK (CDK7-cyclin H). The lack of phosphorylation of CDK9DN or CDK9TA was not due to the loss of CAK activity because CAK could actively phosphorylate histone H1 (Fig. 4A, lane 2). Therefore, threonine 186 of CDK9 is apparently not a substrate site of CAK, because CDK9DN, which contains this threonine, was not phosphorylated by CAK. Second, the CDK9-cyclin T complex was tested as a substrate instead of a CDK9 monomer in a CAK assay because the associated cyclin might induce a structural change in the T-loop. In parallel, CDK2-cyclin A was used as a positive control for the CAK assay. Confirming previous results, CDK2-cyclin A has negligible ability to autophosphorylate, whereas the level of phosphorylation of CDK2-cyclin A was increased about 68-fold in the presence of CAK (Fig. 4, B and C). Unlike CDK2-cyclin A, phosphorylation of the CDK9 subunit of the CDK9-cyclin T complex was not increased by CAK. (Fig. 4, B and C). These observations strongly suggest that CDK9 is not phosphorylated by CAK at either threonine 186 or any other residue(s). The phosphorylation of CDK9 appears to be due to its autokinase activity.



View larger version (23K):
[in this window]
[in a new window]
 
Fig. 4.   CAK assay with CDK9 proteins as substrate. A, in vitro CDK7-cyclin H kinase assay with various CDK9 proteins and histone H1. 20 ng of CDK9 proteins and 100 ng of histone H1 proteins were used in the CAK assay. Positions of phosphorylated CDK7, CDK9, and histone H1 are indicated with arrows. B, 50 ng of CDK9-cyclin T complex and 50 ng of CDK2-cyclin A complex were incubated in the absence or presence of CAK (20 ng) assay. C, quantitation of phosphorylated CDK2, CDK7, and CDK9 proteins from B as determined using a PhosphorImager.

We also tested whether P-TEFb kinase activity might be cooperatively regulated by CAK. In this case, P-TEFb kinase activities were examined using two substrates, hSPT5 and GST·CTD, in the absence or presence of CAK. As shown in Fig. 5, A and B, CDK2-cyclin A kinase activity was greatly enhanced by CAK (105-fold or more), whereas the P-TEFb kinase activity for either substrate hSPT5 or GST·CTD was barely changed by CAK. When different CDK substrates (GST·CTD (a common substrate of P-TEFb, CAK, and CDK2-cyclin A) and hSPT5 (a P-TEFb-specific substrate)) were compared, each of these kinase combinations showed a similar pattern of substrate phosphorylation. We conclude that the CDK9 kinase activity of P-TEFb is independent of CAK.



View larger version (34K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of CAK on P-TEFb kinase activity. A, the kinase activity of CDK9-cyclin T and CDK2-cyclin A complexes was examined in the absence or presence of CAK (CDK7-cyclin H). Recombinant hSPT5 (lanes 2 and 3) and GST·CTD (lanes 5 and 6) proteins were used for the CDK9-cyclin T kinase assay. For CDK2-cyclin A kinase, GST·CTD was used (lanes 7 and 8). CAK (CDK7-cyclin H) was incubated with the CDK9-cyclin T complex (lanes 3 and 6) and CDK2-cyclin A (lane 8). Positions of phosphorylated hSPT5, GST·CTD, CDK9, and CDK7 are marked. B, quantitation of phosphorylated hSPT5 and GST·CTD from A.

Phosphorylation of CDK9 and Kinase Activity-- CDK9 is autophosphorylated on Thr-186 in the T-loop. To test whether this autophosphorylation further activated the kinase, CDK9 was preincubated with ATP to form phosphorylated CDK9. Then the kinase activities of CDK9 with or without preincubation were compared. As shown in Fig. 6, the degree of phosphorylation of CDK9 was increased in an ATP preincubation-dependent manner (Fig. 6A, lanes 2, 4, 6, and 8). However, the phosphorylation of hSPT5 was not increased by preincubation of CDK9 (Fig. 6, A and B). This observation is consistent with Fig. 3, which showed that CDK9TA had kinase activity. Thus, these data suggest that the phosphorylation of CDK9 is not a critical post-translational modification needed for kinase activity.



View larger version (43K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of phosphorylation of CDK9 on P-TEFb kinase activity. A, CDK9WT or the CDK9-cyclin T complex was preincubated with cold ATP (10 µM) for 5 min at 30 °C (lanes 2, 4, 6, and 8). Then recombinant hSPT5 protein (25 ng) was added to kinase reactions (lanes 3, 4, 7, and 8). Positions of phosphorylated hSPT5 and CDK9 are indicated with an arrowhead and arrows, respectively. B, quantitation of phosphorylated CDK9 protein or hSPT5 protein from A.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The results presented indicate that P-TEFb, composed of CDK9 and cyclin T, preferentially phosphorylates hSPT5 as compared with the CTD of RNA Pol II in vitro. Furthermore, the CDK9 kinase is not regulated by CAK even though it contains a conserved threonine common to many CAK-activated CDKs. These results suggest that P-TEFb in a CAK-independent manner could activate Tat-dependent elongation by phosphorylating hSPT5 as well as the CTD of RNA Pol II.

The CDK7 kinase of TFIIH probably has at least two distinct functions in cells. Several studies indicate that CDK7 regulates RNA Pol II activity by phosphorylation of its CTD. In addition, because CDK7 phosphorylates the conserved threonine of CDK2 and other CDKs, it is also thought to be a regulator of the cell cycle machinery (48). A functional role for CDK7 in Tat-stimulated elongation is still controversial. Several studies with CAK inhibitors support the idea that CDK7-cyclin H is also important for Tat activation (38, 39). However, there is accumulating evidence that P-TEFb is the major kinase involved in Tat-activated transcription (12, 16). Recently, the physical association of elongating RNA Pol II with P-TEFb, but not with CAK, provided strong evidence for the primacy of P-TEFb in Tat-dependent elongation (17).

We have tested whether CAK phosphorylation of the CDK9 component of P-TEFb would modulate the activity of this kinase. This does not appear to be the case, because CDK9 phosphorylation did not increase by incubation with CAK, and the kinase activity of CDK9 was not enhanced by CAK. The finding that a catalytically inactive mutant of CKD9, which is defective for autophosphorylation, was not detectably phosphorylated by CAK is the most direct evidence for the former. CDK9 autophosphorylation was observed with the WT kinase and was inactivated by mutation of threonine 186 to alanine. This change did not alter the kinase activity of P-TEFb for either CTD or SPT5. The observation that the threonine 186 to alanine mutant protein is not autophosphorylated appears to conflict with results reporting that CDK9 will autophosphorylate its carboxyl terminus and that this modification is important for binding to TAR (57, 58). The explanation may be that the reactions in this study contained lower concentrations of the CDK9 kinase and were incubated for much briefer periods of time than the previous work. We tested whether CAK-partially phosphorylated CTD of RNA Pol II was a preferred substrate for P-TEFb. However, this was not the case, because phosphorylation of GST·CTD by P-TEFb alone was not significantly different from P-TEFb plus CAK. Taken together, it is likely that CAK and P-TEFb work in an independent manner in RNA Pol II-dependent transcription.

The kinase activity of P-TEFb is important for CTD phosphorylation of RNA Pol II, which correlates with efficient elongation (9, 11). DSIF, composed of hSPT4 and hSPT5, was originally purified on the basis of rendering transcription in vitro dependent upon P-TEFb and thus inhibitable by DRB (31-33). Furthermore, a newly identified negative elongation factor complex works in conjunction with DSIF to stall elongation of RNA Pol II shortly after initiation (34). Extensive studies by Handa and coworkers (32-34) suggest that P-TEFb stimulates RNA Pol II elongation from this position by CTD phosphorylation. Thus, the kinase activity of P-TEFb alleviates the repression activity of DSIF at an early stage of elongation (32).

Many studies have also shown that P-TEFb is critical for HIV-1 Tat-activated transcription elongation (12). For example, the sensitivity to inhibition by the drug DRB and other compounds of Tat activation of transcription in vivo corresponds to the sensitivity of the kinase activity of P-TEFb but not of other known CDKs (10). DSIF is also important for Tat activation of elongation, as shown by depleting reactions in vitro of this complex. Other evidence that Spt5 functions in a positive mode in elongation is the phenotype of mutations in this gene in yeast. Loss of function mutants can have a decreased efficiency of elongation (35).

Phosphorylation of SPT5 by P-TEFb could be important in Tat activation of elongation. This kinase preferentially phosphorylates the repetitive carboxyl domain of SPT5, which is necessary to observe Tat activation in vitro (56). The opposing roles of SPT5 in elongation, inhibition, and stimulation could reflect roles in two processes. In the promoter proximal process, SPT4 and 5 (DSIF) stalls polymerase elongation, which is relieved by phosphorylation by P-TEFb probably of the CTD of Pol II (32). This process has been well documented in vitro for many promoters. A second process, which for HIV is Tat-mediated and dependent upon TAR, probably forms after polymerase has elongated beyond the TAR element. This process would depend upon P-TEFb, bound to TAR in the presence of Tat, interacting with SPT5, probably by phosphorylation, to stimulate elongation over long segments of the template. The existence of two P-TEFb-dependent processes would be consistent with the results of Fong and Zhou (58) and would explain why cyclin T from sources other than humans can function in general transcription from the HIV promoter, but only human cyclin T can function in Tat-dependent stimulation of transcription (14). Finally, recent evidence showing that SPT5 and SPT6 are associated with elongating polymerase, whereas SPT4 and SPT5 (as DSIF) are adequate for promoter proximal events, further supports two roles for SPT5 (59, 60).


    ACKNOWLEDGEMENTS

We thank K. B. Lee, D. Dykxhoorn, D. Tantin, and V. Wang for valuable advice and helpful comments. We also thank M. Siafaca for assistance with the preparation of the manuscript.


    FOOTNOTES

* This work was supported by United States Public Health Service Grants RO1-AI32486 and PO1-CA42063 from the National Institutes of Health and partially by NCI, National Institutes of Health, Cancer Center Support (core) Grant P30-CA14051.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ A Special Fellow of The Leukemia & Lymphoma Society and currently supported by a BK21 Research Fellowship from the Ministry of Education and Human Resources Development and SNU Research Fund.

|| To whom correspondence should be addressed. Tel.: 617-253-6421; Fax: 617-253-3867; E-mail: sharppa@mit.edu.

Published, JBC Papers in Press, January 5, 2001, DOI 10.1074/jbc.M010908200


    ABBREVIATIONS

The abbreviations used are: HIV, human immunodeficiency virus; TAR, transactivation response element; Pol, polymerase; P-TEFb, positive transcription elongation factor b; CDK, cyclin-dependent kinase; CTD, carboxyl-terminal domain; CAK, CDK-activating kinase; aa, amino acids; GST, glutathione S-transferase; FL, full-length; DRB, 5,6-dichloro-beta -D-ribofuranosylbenzimidazole; WT, wild type; CTR, carboxyl-terminal repeat.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Cullen, B. R. (1993) Cell 93, 685-692
2. Emerman, M., and Malim, M. H. (1998) Science 280, 1880-1884[Abstract/Free Full Text]
3. Jones, K. A. (1997) Genes Dev. 11, 2593-2599[Free Full Text]
4. Feng, S., and Holland, E. C. (1988) Nature 334, 165-167[CrossRef][Medline] [Order article via Infotrieve]
5. Ratnasabapathy, R., Sheldon, M., Johal, L., and Hernandez, N. (1990) Genes Dev. 4, 2061-2074[Abstract]
6. Marciniak, R. A., Calnan, B. J., Frankel, A. D., and Sharp, P. A. (1990) Cell 63, 791-802[Medline] [Order article via Infotrieve]
7. Marciniak, R. A., and Sharp, P. A. (1991) EMBO J. 10, 4189-4196[Abstract]
8. Marshall, N. F., Peng, J., Xie, Z., and Price, D. H. (1996) J. Biol. Chem. 271, 27176-27183[Abstract/Free Full Text]
9. Marshall, N. F., and Price, D. H. (1995) J. Biol. Chem. 270, 12335-12338[Abstract/Free Full Text]
10. Mancebo, H. S., Lee, G., Flygare, J., Tomassini, J., Luu, P., Zhu, Y., Peng, J., Blau, C., Hazuda, D., Price, D., and Flores, O. (1997) Genes Dev. 11, 2633-2644[Abstract/Free Full Text]
11. Zhu, Y., Pe'ery, T., Peng, J., Ramanathan, Y., Marshall, N., Marshall, T., Amendt, B., Mathews, M. B., and Price, D. H. (1997) Genes Dev. 11, 2622-2632[Abstract/Free Full Text]
12. Price, D. H. (2000) Mol. Cell. Biol. 20, 2629-2634[Free Full Text]
13. Wei, P., Garber, M. E., Fang, S. M., Fischer, W. H., and Jones, K. A. (1998) Cell 92, 451-462[Medline] [Order article via Infotrieve]
14. Peng, J., Zhu, Y., Milton, J. T., and Price, D. H. (1998) Genes Dev. 12, 755-762[Abstract/Free Full Text]
15. Peng, J., Marshall, N. F., and Price, D. H. (1998) J. Biol. Chem. 273, 13855-13860[Abstract/Free Full Text]
16. Chen, D., and Zhou, Q. (1999) Mol. Cell. Biol. 19, 2863-2871[Abstract/Free Full Text]
17. Ping, Y. H., and Rana, T. M. (1999) J. Biol. Chem. 274, 7399-7404[Abstract/Free Full Text]
18. Isel, C., and Karn, J. (1999) J. Mol. Biol. 290, 929-941[CrossRef][Medline] [Order article via Infotrieve]
19. Garber, M. E., Wei, P., KewalRamani, V. N., Mayall, T. P., Hermann, C. H., Rice, A. P., Littman, D. R., and Jones, K. A. (1998) Genes Dev. 12, 3512-3527[Abstract/Free Full Text]
20. Bieniasz, P. D., Grdina, T. A., Bogerd, H. P., and Cullen, B. R. (1998) EMBO J. 17, 7056-7065[Abstract/Free Full Text]
21. Fujinaga, K., Taube, R., Wimmer, J., Cujec, T. P., and Peterlin, B. M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1285-1290[Abstract/Free Full Text]
22. Chen, D., Fong, Y., and Zhou, Q. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 2728-2733[Abstract/Free Full Text]
23. Kwak, Y. T., Ivanov, D., Guo, J., Nee, E., and Gaynor, R. B. (1999) J. Mol. Biol. 288, 57-69[CrossRef][Medline] [Order article via Infotrieve]
24. Zhou, Q., Chen, D., Pierstorff, E., and Luo, K. (1998) EMBO J. 17, 3681-3691[Abstract/Free Full Text]
25. Zhou, Q., and Sharp, P. A. (1995) EMBO J. 14, 321-328[Abstract]
26. Zhou, Q., and Sharp, P. A. (1996) Science 274, 605-610[Abstract/Free Full Text]
27. Kim, J. B., Yamaguchi, Y., Wada, T., Handa, H., and Sharp, P. A. (1999) Mol. Cell. Biol. 19, 5960-5968[Abstract/Free Full Text]
28. Li, X. Y., and Green, M. R. (1998) Genes Dev. 12, 2992-2996[Abstract/Free Full Text]
29. Wu-Baer, F., Lane, W. S., and Gaynor, R. B. (1998) J. Mol. Biol. 277, 179-197[CrossRef][Medline] [Order article via Infotrieve]
30. Parada, C. A., and Roeder, R. G. (1999) EMBO J. 18, 3688-3701[Abstract/Free Full Text]
31. Wada, T., Takagi, T., Yamaguchi, Y., Ferdous, A., Imai, T., Hirose, S., Sugimoto, S., Yano, K., Hartzog, G. A., Winston, F., Buratowski, S., and Handa, H. (1998) Genes Dev. 12, 343-356[Abstract/Free Full Text]
32. Wada, T., Takagi, T., Yamaguchi, Y., Watanabe, D., and Handa, H. (1998) EMBO J. 17, 7395-7403[Abstract/Free Full Text]
33. Yamaguchi, Y., Wada, T., Watanabe, D., Takagi, T., Hasegawa, J., and Handa, H. (1999) J. Biol. Chem. 274, 8085-8092[Abstract/Free Full Text]
34. Yamaguchi, Y., Takagi, T., Wada, T., Yano, K., Furuya, A., Sugimoto, S., Hasegawa, J., and Handa, H. (1999) Cell 97, 41-51[Medline] [Order article via Infotrieve]
35. Hartzog, G. A., Wada, T., Handa, H., and Winston, F. (1998) Genes Dev. 12, 357-369[Abstract/Free Full Text]
36. Garcia-Martinez, L. F., Mavankal, G., Neveu, J. M., Lane, W. S., Ivanov, D., and Gaynor, R. B. (1997) EMBO J. 16, 2836-2850[Abstract/Free Full Text]
37. Parada, C. A., and Roeder, R. G. (1996) Nature 384, 375-378[CrossRef][Medline] [Order article via Infotrieve]
38. Yankulov, K., Yamashita, K., Roy, R., Egly, J. M., and Bently, D. L. (1995) J. Biol. Chem. 270, 23922-23925[Abstract/Free Full Text]
39. Cujec, T. P., Okamoto, H., Fujinaga, K., Meyer, J., Chamberlin, H., Morgan, D. O., and Peterlin, B. M. (1997) Genes Dev. 11, 2645-2657[Abstract/Free Full Text]
40. Holstege, F. C. P., and Young, R. A. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 2-4[Free Full Text]
41. Svejstrup, J. Q., Vichi, P., and Egly, J. M. (1996) Trends Biochem. Sci. 20, 346-350[CrossRef]
42. Hoeijmakers, J. H. J., Egly, J. M., and Vermeulen, W. (1996) Curr. Opin. Genet. Dev. 6, 26-33[Medline] [Order article via Infotrieve]
43. Hampsey, M. (1998) Microbiol. Mol. Biol. Rev. 62, 465-503[Abstract/Free Full Text]
44. Tirode, F., Busso, D., Coin, F., and Egly, J.-M. (1999) Mol. Cell 3, 87-95[Medline] [Order article via Infotrieve]
45. Cho, E. J., Takagi, T., Moore, C. R., and Buratowski, S. (1997) Genes Dev. 11, 3319-3326[Abstract/Free Full Text]
46. Rodriguez, C. R., Cho, E. J., Keogh, M. C., Moore, C. L., Greenleaf, A. L., and Buratowski, S. (2000) Mol. Cell. Biol. 20, 104-112[Abstract/Free Full Text]
47. Hirose, Y., and Manley, J. L. (2000) Genes Dev. 14, 1415-1429[Free Full Text]
48. Morgan, D. O. (1995) Nature 374, 131-134[CrossRef][Medline] [Order article via Infotrieve]
49. Dynlacht, B. D. (1997) Nature 389, 149-152[CrossRef][Medline] [Order article via Infotrieve]
50. Kamps, M. P., and Sefton, B. M. (1989) Anal. Biochem. 176, 22-27[Medline] [Order article via Infotrieve]
51. van der Geer, P., and Hunter, T. (1994) Electrophoresis 15, 544-554[Medline] [Order article via Infotrieve]
52. Sehgal, P. B., Darnell, J. E., and Tamm, I. (1976) Cell 9, 473-480[Medline] [Order article via Infotrieve]
53. Tamm, I., Hand, R., and Caliguiri, L. A. (1976) J. Cell Biol. 69, 229-240[Abstract]
54. Egyhazi, E. (1974) J. Mol. Biol. 84, 173-183[Medline] [Order article via Infotrieve]
55. Chodosh, L. A., Fire, A., Samuels, M., and Sharp, P. A. (1989) J. Biol. Chem. 264, 2250-2257[Abstract/Free Full Text]
56. Ivanov, D., Kwak, Y. T., Guo, J., and Gaynor, R. B. (2000) Mol. Cell. Biol. 20, 2970-2983[Abstract/Free Full Text]
57. Garber, M. E., Mayall, T. P., Suess, E. M., Meisenhelder, J., Thompson, N. E., and Jones, K. A. (2000) Mol. Cell Biol. 20, 6958-6969[Abstract/Free Full Text]
58. Fong, Y. W., and Zhou, Q. (2000) Mol. Cell. Biol. 20, 5879-5907[Abstract/Free Full Text]
59. Kaplan, C. D., Morris, J. R., Wu, C.-t., and Winston, F. (2000) Genes Dev. 14, 2623-2634[Abstract/Free Full Text]
60. Andrulis, E. D., Guzman, E., Doring, P., Werner, J., and Lis, J. T. (2000) Genes Dev. 14, 2635-2649[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.